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Recent progress in risk-adapted treatment for childhood acute lymphoblastic leukemia has secured 5-year
event-free survival rates of approximately 80% and 5-year survival rates approaching 90%. With improved
systemic and intrathecal chemotherapy, it is now feasible to omit safely in all patients prophylactic cranial
irradiation, which was once a standard treatment. As high-resolution, genome-wide analyses of leukemic
and normal host cells continue to identify novel subtypes of lymphoblastic leukemia and provide new in-
sights into leukemogenesis, we can look forward to the time when all cases of this disease will be classified
according to specific genetic abnormalities, some of which will yield “druggable” targets for more effective
and less toxic treatments. Meanwhile, it is sobering to consider that a significant fraction of leukemia sur-
vivors will develop serious health problems within 30 years of their initial diagnosis. This underlines the
need to introduce early countermeasures to reduce late therapy-related effects. The ultimate challenge is 
to gain a clear understanding of the factors that give rise to childhood leukemia in the first place, and 
enable preventive strategies to be devised and implemented.
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Acute lymphoblastic leukemia (ALL) is the most
common pediatric cancer, accounting for a quarter
of all malignancies diagnosed among children aged
< 15 years. This potentially catastrophic disease
was once fatal in four-fifths of patients, but its clin-
ical outcome has improved remarkably over the
past 50 years (Figure), with event-free and overall
survival rates in contemporary trials ranging from
72.1% to 85.6% and 83.0% to 93.5%, respectively
(Table 1).1–14 As treatment efficacy has reached
optimal levels for most patients, the prognostic
significance of conventional risk factors such as
male sex, black race and hyperleukocytosis has
diminished or disappeared.11,15 We are left with
only a few disease subtypes that remain a challenge
to therapists [infant ALL with MLL (mixed lineage
leukemia) rearrangement, hypodiploidy with < 44
chromosomes, and cases resistant to early treat-
ment are good examples]. Major concerns of the
leukemia research community include the develop-
ment of strategies to combat these cases effectively
and to target crucial leukemogenic pathways in
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individual patients, and minimizing the risk of
acute or late side effects. This article reviews the
progress that has been made towards achieving
these and other goals.
Diagnosis, Classification and 
Genetic Alterations
Immunophenotyping by flow cytometry is es-
sential to make a diagnosis of ALL and distin-
guish subtypes with therapeutic implications,
including B-cell precursor ALL, mature (Burkitt)
ALL and T-cell ALL. Recently, using a combina-
tion of flow cytometry, gene expression profiling
and single nucleotide polymorphism (SNP) array
analysis, Coustan-Smith et al16 have identified a
unique T-cell ALL subtype termed early T-cell
precursor (ETP) leukemia, with an exceptionally
poor response to lymphoid-cell-directed therapy.
The transformed thymocytes in ETP-ALL appear
to arise from stem-cell-like thymic precursors that
have recently migrated from the bone marrow to
the thymus. Early recognition of these cases, using
immunophenotypic criteria, is essential for the
C.H. Pui
778 J Formos Med Assoc | 2010 • Vol 109 • No 11
Table 1. Results of recently completed clinical trials for acute lymphoblastic leukemia
Study Years of study
No. of Age range Event-free survival Survival at
Reference
patients (yr) at 5 yr (% ± SE) 5 yr (% ± SE)
AIEOP-95 1995–2000 1743 0–17 75.9 ± 1.0 85.5 ± 0.8 Conter et al [1]
BFM-95 1995–2000 2169 0–18 79.6 ± 0.9 86.3 ± 0.6 Möricke et al [2]
CCG-1900 1996–2002 4464 0–21 76.0 ± 0.7 86.3 ± 0.6 Gaynon et al [3]
COALL-7 1997–2003 667 0–18 76.7 ± 1.7 85.4 ± 1.4 Escherich et al [4]
CPH-95 1996–2002 380 0–18 72.1 ± 2.3 83.0 ± 1.9 Stary et al [5]
DCOG-9 1997–2004 859 1–18 80.6 ± 1.4 86.4 ± 1.2 Kamps et al [6]
DFCI 00-01 2000–2004 492 0–18 80.0 ± 2.0 91.0 ± 1.0 Vrooman et al [7]
INS 98 1998–2003 315 0–18 78.7 ± 2.3 83.8 ± 2.1 Stark et al [8]
NOPHO-2000 2002–2007 1023 1–15 79.4 ± 1.5 89.1 ± 1.1 Schmiegelow et al [9]
SJCRH-13B 1994–1998 247 0–18 80.1 ± 2.6 85.7 ± 2.2 Pui et al [10]
SJCRH-15 2000–2007 498 1–18 85.6 ± 2.9 93.5 ± 1.9 Pui et al [11]
TCCSG-95-14 1995–1999 597 1–15 76.8 ± 1.8 84.9 ± 1.5 Tscuhida et al [12]
TPOG-2002 2002–2007 788 0–18 77.4 ± 1.7 83.5 ± 1.6 Liang et al [13]
UKALL-97/99 1999–2002 938 1–18 80.0 ± 1.2 88.0 ± 1.1 Mitchell et al [14]
AIEOP = Associazione Italiana di Ematologia ed Oncologia Pediatrica; BFM = Berlin–Frankfurt–Münster ALL Study Group; CCG = Children’s
Cancer Group; COALL = Cooperative ALL Study Group; CPH = Pediatric Hematology in the Czech Republic; DCOG = Dutch Childhood Oncology
Group; DFCI = Dana–Farber Cancer Institute ALL Consortium; INS = Israeli National Studies of Childhood ALL; NOPHO = Nordic Society of
Pediatric Hematology and Oncology; SJCRH = St. Jude Children’s Research Hospital; TCCSG = Tokyo Children’s Cancer Study Group; TPOG =
Taiwan Pediatric Oncology Group; UKALL = UK Medical Research Council Working Party on Childhood Leukaemia. SE = Standard error.
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Figure. Kaplan–Meier analysis of survival for 2852 children
with newly diagnosed acute lymphoblastic leukemia treated
in 15 consecutive studies at St. Jude Children's Research
Hospital from 1962 to 2007. Five-year survival estimates
are shown. The results demonstrate steady improvement
in outcome over the past 40 years.
development of an effective clinical management
strategy for ETP-ALL.
Leukemic lymphoblasts often express myeloid-
associated antigens, whose pattern of expression
can be correlated with specific genetic subtypes
of ALL. For example, MLL-rearranged ALL cases
express CD15, CD33 and CD65, and those with
the ETV6-RUNX1 (also known as TEL-AML1) 
fusion gene express CD13 and CD33. Expression
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of myeloid-associated antigens can be useful in im-
munological monitoring of patients for minimal
residual leukemia, although it lacks prognostic
significance in ALL.17 By contrast, a subset of cases
co-express lymphoid- and myeloid-associated
markers but do not cluster with T-cell, B-cell pre-
cursor or acute myeloid leukemia in gene expres-
sion profiling. It is important to recognize these
cases at diagnosis because they might respond
poorly to myeloid-directed therapy, which requires
a switch to ALL-directed induction treatment.18
ALL arises from lymphoid progenitor cells that
carry specific genetic and epigenetic alterations.
Therefore, analysis of these changes yields more
relevant biological information than does any
other approach. Using standard molecular meth-
ods, one can detect primary genetic abnormalities
in approximately 75% of ALL cases but cannot
identify the full repertoire of genetic alter-
ations.17,19 With the availability of high-resolution,
genome-wide analysis of gene expression, DNA
copy number alterations (CNAs) and epigenetic
changes, the potential to fully characterize a pa-
tient’s genetic makeup fully has increased enor-
mously. Currently, virtually all patients with ALL
can be classified according to specific genetic 
abnormalities.20
Experimental models have established that
cooperative mutations are necessary to induce
leukemia and contribute to the development of
drug resistance. Using SNP arrays, Mullighan et al21
identified an average of six CNAs per case of child-
hood ALL. These lesions target genes that regu-
late lymphoid differentiation, tumor suppression,
the cell cycle, apoptosis, signaling pathways,
MicroRNAs, and drug responsiveness. There are
substantial differences in the frequency of CNAs
among various leukemia subtypes. Although cases
with ETV6-RUNX1 or BCR-ABL1 have over six le-
sions per case, MLL-rearranged ALL has fewer than
one CNA per case, which suggests that MLL is a
potent oncogene that requires very few cooperat-
ing mutations to induce leukemic transformation.
Indeed, MLL-rearranged leukemia often presents
during infancy and has a concordance rate close
to 100% in identical twins, which indicates in utero
development and transplacental metastasis from
one fetus to the other.17
In Philadelphia chromosome-positive (Ph+)
ALL with BCR-ABL1 fusion, IKZF1 is deleted in
approximately 80% of the cases.22 One high-risk
subtype of BCR-ABL1-negative ALL is characterized
by IKZF1 deletion, and has a genetic profile simi-
lar to that of cases with BCR-ABL1 fusion.23,24 In
studies to detect activated tyrosine kinase signaling
in this leukemia subtype, Mullighan et al25 identi-
fied activating JAK mutations in approximately
10% of high-risk BCR-ABL1-negative cases. Fur-
ther analyses have revealed CRLF2 overexpression
in 6–7% of B-cell precursor ALL cases, and notably,
in 50–60% of patients with Down-syndrome-
associated ALL.26–29 CRLF2 alteration is also as-
sociated with activating JAK mutations; indeed, 
a combination of these two genetic lesions re-
sults in the growth of cytokine-dependent mouse
B-progenitor cell lines in the absence of exogenous
cytokines, which indicates that they are cooperative
mutations in leukemogenesis.26,29
The most daunting challenge in the molecular
diagnosis of all subtypes of ALL is to distinguish
events that drive the continued growth or survival
of the leukemic clone from those that simply re-
flect genetic epiphenomena. Otherwise, it will be
difficult to translate the insights provided by emerg-
ing DNA and RNA technologies into improved
patient care.
Mechanisms of Treatment Resistance
and Relapse
Genome-wide studies using matched diagnosis
and relapse samples from the same patients have
shown that both sets of samples are clonally re-
lated, and that the relapse clones are often present
as minor populations at diagnosis, which suggests
that they are selected during treatment. Indeed,
many of the genetic alterations that emerge in
the dominant clone at relapse involve genes that
have been implicated in treatment resistance
(e.g. CDKN2A/B or IKZF1),30,31 and gene expres-
sion studies have identified a proliferative gene
C.H. Pui
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signature that emerges at relapse with consistent
upregulation of genes, such as survivin, that
could provide useful targets for novel therapeutic
intervention.32
Inherited Susceptibility to ALL
Inherited genetic syndromes, such as Down or
Bloom syndrome, account for only a small fraction
of ALL cases (< 5%). A more promising research
avenue is the notion that relatively frequent genetic
polymorphisms can interact with environmental,
dietary and other external factors to increase the
likelihood of leukemia induction.
Candidate gene approaches have implicated
inherited polymorphisms of several genes in leu-
kemogenesis but the findings have not been con-
sistent. Recent genome-wide studies on patients
of European ancestry have failed to confirm these
previously reported gene associations, but inde-
pendently they have identified that germline poly-
morphisms of the IKZF1 and ARID5B genes are
associated with an increased risk of childhood
ALL.33,34 The risk alleles of ARID5B are specifically
enriched in patients with hyperdiploid ALL, and
are also associated with greater methotrexate poly-
glutamate accumulation.33,34 Thus, the same ge-
netic variation of ARID5B that predisposes to the
development of hyperdiploid ALL also underlies
the superior response of this subtype of ALL to
methotrexate treatment. A subsequent study in
patients of African ancestry has shown that
ARID5B germline polymorphisms are also asso-
ciated with the risk of developing hyperdiploid
ALL in black patients.35 The lower frequency of
this risk allele in the control populations of
African ancestry compared to those of European
ancestry could also partly explain the lower inci-
dence of hyperdiploid ALL in black patients.
Factors Influencing Risk Classification
Despite the promise of ALL management based on
specific genetic lesions, current approaches to risk
assessment still rely on a number of key clinical
and laboratory findings, such as the initial leuko-
cyte count, age at diagnosis and early treatment
response.36 Children aged 1–9 years have a better
outcome than infants and adolescents. Leukocyte
count is a continuous variable, with decreasing
counts conferring a better outcome. A presenting
age between 1–9 years and a leukocyte count
< 50 × 109/L are minimal criteria for low-risk B-cell
precursor ALL, but carry little prognostic value 
in T-cell ALL. The prognostic impact of age and
leukocyte count can be partly explained by their
association with specific genetic abnormalities.
For example, there is a preponderance of cases
with favorable genetic abnormalities of hyper-
diploidy > 50 chromosomes or ETV6-RUNX1 in
patients aged 1–9 years.36 It should be stressed
that even so-called low-risk ALL cases need a cer-
tain degree of treatment intensification to avoid
unacceptable rates of relapse. Table 2 lists the
factors commonly used for risk and therapeutic
stratification in current clinical trials.
Although many genetic abnormalities, includ-
ing some identified recently, are associated with
Table 2. Factors commonly used for risk stratification
Factors Favorable Adverse
Age (yr) 1–9 < 1 or ≥ 10
Leukocyte count (× 109/L) < 50 > 50
Immunophenotype B-cell precursor T-cell
Genotype Hyperdiploidy > 50 chromosomes Hypodiploidy < 44 chromosomes
ETV6-RUNX1 BCR-ABL1
MLL-AF4
Minimal residual disease after induction < 0.01% ≥ 1%
Childhood acute lymphoblastic leukemia 
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clinical outcome, only a few are routinely used for
treatment stratification (Table 2), largely because
too few cases of these lesions have been studied to
validate any apparent effects on prognosis. Adverse
genetic abnormalities include MLL rearrangements
and hypodiploidy < 44 chromosomes.17,36 Ph+
ALL was once considered to be a very high-risk
form of leukemia, even when treatment included
matched-related hematopoietic stem cell trans-
plantation.37 The prospects for a favorable thera-
peutic outcome in patients with Ph+ ALL have
improved markedly, as demonstrated in a recent
study that has combined intensive chemotherapy
with a tyrosine kinase inhibitor (imatinib mesy-
late).38 It should be stressed that each specific ge-
netic subtype identified to date might show
considerable clinical heterogeneity. For example,
even among patients with Ph+ ALL, patients aged
1–9 years fare significantly better than older pa-
tients,37 and among patients with MLL-rearranged
ALL, young infants have the worst outcome.39
The basis of these differences might be related to
secondary genetic events, the developmental stage
of the target cell undergoing malignant transfor-
mation, and the pharmacogenetics or pharmaco-
kinetic features of the patient.
The most useful prognostic factor is the re-
sponse to early treatment, as determined by mea-
surements of the rate of clearance of leukemic cells
from the blood or bone marrow. This estimate of
minimal residual disease accounts for the drug
sensitivity or resistance of leukemic cells and the
pharmacodynamics of the drugs, which is affected
by the pharmacogenetics of the host.40 Flow cyto-
metric profiling of aberrant immunophenotypes
and polymerase chain reaction amplification of
fusion transcripts or antigen-receptor genes, which
are at least 100-fold more sensitive than conven-
tional morphological determinants, have allowed
minimal residual disease to be detected at very
low levels (< 0.01%). This provides a useful means
to identify patients at very low or high risk of re-
lapse. Patients with ≥ 1% leukemic cells after re-
mission induction fare almost as poorly as those
who fail to achieve clinical remission by the con-
ventional morphological standard (≥5% leukemic
cells), whereas those who achieve molecular or
immunologic remission (< 0.01%) have an excel-
lent outcome.40,41 Minimal residual disease can
be measured by the current techniques in nearly
all patients, and has become a crucial factor for
risk stratification in childhood ALL.
Advances in Treatment
Supportive care
Optimal management of patients with ALL re-
quires careful attention to supportive care. Hyper-
uricemia and hyperphosphatemia with secondary
hypocalcemia are frequently encountered, even
before chemotherapy is initiated, especially in pa-
tients with a high leukemic cell burden and those
with T-cell or mature B-cell ALL. Rasburicase (re-
combinant urate oxidase), a potent uricolytic agent,
rapidly decreases serum uric acid level, improves
renal function and facilitates the excretion of phos-
phorus.42 Even in patients with massive tumor
lysis, the combined use of rasburicase (followed by
allopurinol), adequate hydration and a phosphate
binder can prevent acute renal failure and avoid
the need for hemodialysis in the vast majority 
of patients.
Remission induction
Rates of complete remission range from 97% to
99% with the use of contemporary chemother-
apy.1–14 Induction regimens typically include a
glucocorticoid (prednisone, prednisolone or dex-
amethasone), vincristine, and asparaginase. Chil-
dren with high- or very-high-risk ALL receive one
or more additional drugs including an anthracyline
and cyclophosphamide; however, intensification
of induction therapy can lead to increased mor-
bidity and mortality. In one study, the use of high-
dose dexamethasone (10 mg/m2/day) instead of
prednisone (60 mg/m2/day) improved leukemia
control in patients with T-cell ALL but resulted in
a high mortality rate, especially in adolescent pa-
tients.43 Although in most randomized trials, pa-
tients treated with dexamethasone have had a
better outcome than those treated with prednisone,
C.H. Pui
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it is debatable whether dexamethasone is more ef-
fective than prednisone, and one could argue that
the dose of prednisone might have been too low
in these studies.44 Whether intensification of re-
mission induction is even necessary for children
with standard-risk ALL, particularly if they receive
intensive post-induction therapy,3 is also debat-
able. As a result of its lower immunogenicity, less
frequent dosing, and feasibility of intravenous ad-
ministration, pegaspargase (a polyethylene glycol
form of Escherichia coli asparaginase) has replaced
the native product as the first-line treatment for
children in the United States, and it is increasingly
used in clinical trials worldwide.45 Antibodies to
E. coli asparaginase cross-react with pegaspargase;
therefore, patients with allergic reactions to either
form of the enzyme should be treated with a prod-
uct derived from Erwinia chrysanthemi.45 A final
caveat is that antibodies can develop against poly-
ethylene glycol and adversely affect drug efficacy.46
Intensification (consolidation) therapy
Post-remission intensification (consolidation)
therapy improves outcomes, even in patients with
low-risk ALL.3 Commonly used regimens include
high-dose methotrexate with daily mercaptop-
urine, and a combination of high-dose asparagi-
nase given for an extended period together with
vincristine, dexamethasone or lower-dose metho-
trexate.2,3,7,11,36 Patients with ALL and ETV6-RUNX1
fusion had an especially good outcome in clinical
trials that featured intensive post-remission treat-
ment with glucocorticoids, vincristine and as-
paraginase.11,47 Although high-dose methotrexate
(5 g/m2) is associated with improved outcome in
T-cell ALL, lower doses appear to be sufficient for
low-risk B-cell precursor ALL.3,11
Delayed intensification (or re-induction),
which consists of repetition of the initial remission-
induction therapy approximately 3 months after
the end of remission induction, has been an es-
sential treatment component. Although extended
and stronger intensification therapy with aspara-
ginase, methotrexate and vincristine has improved
outcomes for children and adolescents with high-
risk ALL and slow responses to initial induction
therapy, recent studies have demonstrated that early
intensive (rather than extended) post-induction
treatment benefits most patients.11,48,49
Continuation therapy
Weekly methotrexate and daily mercaptopurine
for 2–2.5 years constitute the usual continuation
regimen for ALL. Administration of this combina-
tion to the limits of tolerance (i.e. leukocyte counts
consistently < 3.5 × 109/L) and compliance has
been associated with improved clinical outcomes.50
Approximately 10% of the patients have an
inherited heterozygous deficiency of thiopurine
S-methyltransferase; the enzyme that catalyzes the
S-methylation (inactivation) of mercaptopurine.
Almost half of these patients require moderate re-
ductions in mercaptopurine dosage to prevent se-
vere myelosuppression. Patients with this enzyme
deficiency are also at risk for therapy-related
leukemia.51 A reduction of mercaptopurine dose
might reduce the risk of therapy-related leukemia
in these patients.
Intermittent pulses of vincristine and a gluco-
corticoid have been widely adopted in the treat-
ment of childhood ALL. In an intergroup trial of
initial intensive chemotherapy, the addition of six
pulses of vincristine and dexamethasone during
early continuation treatment failed to improve
clinical outcomes in children with intermediate-
risk ALL.52 However, with a longer follow-up, one
of the groups showed that the pulses of vincris-
tine and corticosteroids improved disease-free
survival, without an accompanying gain in over-
all survival.53 Thus, whether this pulse therapy 
is necessary in contemporary regimens that fea-
ture early intensification of therapy remains to be
determined.
CNS-directed treatment
Systemic treatment including high-dose methotrex-
ate, intensive asparaginase, and dexamethasone,
as well as optimal intrathecal therapy, are impor-
tant in the control of CNS leukemia.54 Thus, triple
intrathecal therapy with methotrexate, cytarabine
and hydrocortisone is more effective than intra-
thecal methotrexate in preventing CNS relapse.55
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Two recent studies have shown that, with effective
intrathecal and systemic chemotherapy, prophy-
lactic cranial irradiation, once a standard CNS-
directed treatment, can be safely omitted from
first-line protocols, even in patients with T-cell
ALL, hyperleukocytosis, or overt CNS leukemia at
diagnosis, all high-risk features for CNS relapse.11,56
The reported 5-year event-free survival rates were
85.6% and 81%, and the isolated CNS relapse
rates were only 2.7% and 2.6%, respectively. Im-
portantly, all 11 patients with isolated CNS relapse
in the first study remained in second remission for
0.4–5.5 years after salvage therapy. This innovative
treatment approach promises to improve the qual-
ity of life of survivors of childhood ALL.
Stem cell transplantation
The indications for hematopoietic stem cell trans-
plantation during first remission must be con-
tinuously reviewed as treatment improves and new
agents become available. Currently, failure to re-
spond, or a poor early response to initial remission
induction treatment (e.g. ≥ 1% blasts), is the most
frequent indication for transplantation. Although
transplantation does not appear to improve out-
come in hypodiploid ALL57 or MLL-rearranged
ALL in infants,39,58,59 many leukemia therapists
still recommend transplantation for patients with
poor early responses to treatment. In view of the
markedly improved early treatment results with
combined use of intensive chemotherapy and a
tyrosine kinase inhibitor (imatinib),38 many in-
vestigators do not recommend transplantation
in first remission for children with BCR-ABL1-
positive ALL, unless they have poor response to
remission induction treatment. Whether transplan-
tation benefits patients with ETP-ALL remains to
be determined.
Targeted therapeutics
Targeted cancer therapy is best defined as a treat-
ment that is designed to modulate a single mo-
lecular target, usually through inhibition but
sometimes through activation. Use of the tyrosine
kinase inhibitor imatinib in BCR-ABL1-positive
ALL offers an excellent example of this approach.
More potent second generation tyrosine kinase
inhibitors (dasatinib and nilotinib) have been
developed to address the problem of resistance to
imatinib.60 Other novel agents with potential roles
in ALL include FLT3 (FMS-like tyrosine kinase 
receptor-3) inhibitors, farnesyltransferase inhib-
itors, proteasome inhibitors, demethylating agents
and histone deacetylase inhibitors.60 Immuno-
therapeutic options are also emerging. Rituximab
(anti-CD20), alemtuzumab (anti-CD52), ino-
tuzumab (anti-CD22) and epratuzumab (anti-
CD22) have already been incorporated into some
clinical trials,20 and recombinant immunotoxins
and bispecific antibodies (blinatumomab) are
being tested.61,62 The chief difficulty with targeted
therapeutics for any cancer is that the molecules
or signaling pathways selected for manipulation
might not be crucial drivers of the malignancy
process. This means that their inhibition or acti-
vation might produce only transient effects on
the cancer, while introducing excessive toxicity in
normal tissues. Also, the curative potential of cy-
totoxic chemotherapy in most cases of childhood
ALL is high, which makes the selection of pediatric
patients for trials of targeted therapies more chal-
lenging, and raises the required level of activity
necessary for success.
Late Complications of Therapy
Cranial irradiation causes many serious late seque-
lae and occasional fatal complications, such as
second cancers, neurocognitive deficits, and endo-
crine abnormalities that can lead to obesity, short
stature, precocious puberty, and osteoporosis.63–66
In general, these complications are seen in girls
more often than in boys, and in young children
more often than in older children. Survivors of
childhood ALL who were treated 20–40 years ago
face a considerable mortality risk during adult-
hood; by one estimate they have an average loss in
life expectancy of 10 years, which is most probably
due to the use of cranial irradiation.67
Contemporary treatment programs have largely
abandoned the use of cranial irradiation and 
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replaced it with intensive systemic and intrathecal
treatment with methotrexate and glucocorticoids,
which leads to a different set of complications.
Short-term complications of glucocorticoid use
include myopathy, myalgia, infection, behavioral
problems, hyperglycemia, and adrenal axis sup-
pression.68 Although these complications are tran-
sient, osteonecrosis induced by glucocorticoids
can be a severely debilitating toxicity that results
in joint collapse that requires total joint replace-
ment.69,70 The pathogenesis of glucocorticoid-
induced osteonecrosis is still being investigated,
but has been variously attributed to intravascular
thrombotic occlusion, adipocyte hypertrophy and
marrow ischemia, as well as apoptosis of endo-
thelial cells, osteoblasts, and osteoclasts.68 Risk
factors for osteonecrosis include age 10–20 years,
high body mass index, female sex, and white
race.69–71 Early identification of bone and joint
lesions for therapeutic intervention is important
for minimizing toxicity. To this end, intermittent
use of dexamethasone (i.e. days 1–7 and 15–21 of
re-induction treatment), even at higher total doses,
appears to have reduced the risk of osteonecrosis
compared with continuous administration of the
drug.49 Additional studies are needed to deter-
mine if such intermittent administration might
compromise leukemia control.
Treatment with anthracyclines can produce se-
vere cardiomyopathy, especially when these agents
are given in high cumulative and peak doses 
to young girls. Cardiac abnormalities are persist-
ent and progressive for years following anthracy-
cline therapy.72 Although dexrazoxane can reduce
anthracycline-induced cardiotoxicity without in-
terfering with antileukemic activity73 or causing
secondary malignant neoplasms,74 the use of an-
thracyclines in current clinical trials is limited,
even for high-risk cases.
Summary
Cure rates for childhood ALL have improved re-
markably over the past 40 years; largely through
intensive use of conventional chemotherapy in the
context of rigorous clinical trials. Clinical factors,
genetic features of the leukemia, initial response
to therapy, and in some clinical trials, pharmaco-
genetics are now used in concert to select treatment
plans for increasingly smaller subsets of patients.
However, the side effects of cytotoxic chemotherapy
remain significant, and a useful mechanistic un-
derstanding of non-responding and drug-resistant
cases is often lacking. Rapid advances in functional
and chemical genomics have made it possible to
identify ever-larger numbers of genetic lesions in
leukemic cells. This, in turn, will soon enable pre-
cise discrimination between patients who are likely
to be cured with antimetabolite-based therapies,
and those who will require more intensive treat-
ment. It will also provide an expanding repertoire
of therapeutic targets for clinical evaluation. Finally,
the recognition of host factors associated with the
risk of leukemic transformation and the response
to therapy will probably lead to more sophisticated
treatment strategies in the near future.
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